Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Girard

Showing results (171-180 of 396) with videos related to

Pageof 40
Sort By:
Expert Review of Anticancer Therapy|November 22, 2014
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?Nicolas Girard, Clarisse Audigier-Valette, Alexis B Cortot, et al.
Cancers|November 9, 2024
Optimizing Treatment Strategies for <i>Egfr</i>-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and InsightsQuentin Dominique Thomas, Nicolas Girard, Lise Bosquet, et al.
Targeted Oncology|September 21, 2022
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French StudyAssya Akli, Nicolas Girard, Vincent Fallet, et al.
Translational Lung Cancer Research|January 9, 2026
A systematic literature review and meta-analysis on the efficacy and safety of PD-(L)1 inhibitors for the first- and second-line treatment of locally advanced or metastatic non-small cell lung cancer in Asian and non-Asian patientsNicolas Girard, Daniel Tan, Diego Cortinovis, et al.
Clinical Lung Cancer|September 9, 2022
Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint InhibitorsNicolas Girard, Anna Minchom, Sai-Hong Ignatius Ou, et al.
Cancers|January 11, 2022
Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort ExperienceTina Lamy, Bastien Cabarrou, David Planchard, et al.
British Journal of Cancer|September 20, 2024
Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLCBoutaîna Chandouri, Thomas Naves, May Yassine, et al.
Journal of Bone Oncology|January 21, 2020
Rapid detection of <i>EGFR</i> mutations in decalcified lung cancer bone metastasisAntoine Boureille, Carole Ferraro-Peyret, Guillaume Pontarollo, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 1, 2015
MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptorLucile Hoch, Helene Faure, Hermine Roudaut, et al.
Drugs - Real World Outcomes|September 17, 2021
European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record ReviewRiyaz Shah, Nicolas Girard, Saurabh P Nagar, et al.
Pageof 40

Showing results (171-180 of 396) with videos related to

Sort By:
Pageof 40
Expert Review of Anticancer Therapy|November 22, 2014
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?Nicolas Girard, Clarisse Audigier-Valette, Alexis B Cortot, et al.
Cancers|November 9, 2024
Optimizing Treatment Strategies for <i>Egfr</i>-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and InsightsQuentin Dominique Thomas, Nicolas Girard, Lise Bosquet, et al.
Targeted Oncology|September 21, 2022
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French StudyAssya Akli, Nicolas Girard, Vincent Fallet, et al.
Translational Lung Cancer Research|January 9, 2026
A systematic literature review and meta-analysis on the efficacy and safety of PD-(L)1 inhibitors for the first- and second-line treatment of locally advanced or metastatic non-small cell lung cancer in Asian and non-Asian patientsNicolas Girard, Daniel Tan, Diego Cortinovis, et al.
Clinical Lung Cancer|September 9, 2022
Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint InhibitorsNicolas Girard, Anna Minchom, Sai-Hong Ignatius Ou, et al.
Cancers|January 11, 2022
Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort ExperienceTina Lamy, Bastien Cabarrou, David Planchard, et al.
British Journal of Cancer|September 20, 2024
Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLCBoutaîna Chandouri, Thomas Naves, May Yassine, et al.
Journal of Bone Oncology|January 21, 2020
Rapid detection of <i>EGFR</i> mutations in decalcified lung cancer bone metastasisAntoine Boureille, Carole Ferraro-Peyret, Guillaume Pontarollo, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 1, 2015
MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptorLucile Hoch, Helene Faure, Hermine Roudaut, et al.
Drugs - Real World Outcomes|September 17, 2021
European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record ReviewRiyaz Shah, Nicolas Girard, Saurabh P Nagar, et al.
Pageof 40